ESTRO 2024 - Abstract Book

S1509

Clinical - Lower GI

ESTRO 2024

Simultaneous analysis of several outcomes prioritized by importance using a Generalized Pairwise Comparison approach did no reveal significant differences between the two TNT sequences. The higher incidence of complete remission after consolidation chemotherapy did not result in better long-term outcome nor in improved quality of life. A Generalized pairwise comparison may be helpful to combine clinical and patient-reported outcomes. However, improving the reporting and measurement of long-term patient-reported quality of life outcomes is essential.

Keywords: clinical trial, rectal cancer, endpoint

References:

1. Fokas E, Allgauer M, Polat B, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO 12. J Clin Oncol. Dec 1 2019;37(34):3212-3222. doi:10.1200/JCO.19.00308 Fokas E, Schlenska-Lange A, Polat B, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. Jan 1 2022;8(1):e215445. doi:10.1001/jamaoncol.2021.5445 2.

3. Buyse M. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Stat Med. Dec 30 2010;29(30):3245-57. doi:10.1002/sim.3923

1339

Digital Poster

Doseescalated proton reirradiation for recurrent anal cancer. First results from the ReRad III trial

Camilla JS Kronborg 1,2 , Bodil G Pedersen 3 , Heidi S Rønde 1 , Jesper F Kallehauge 1 , Eva Serup-Hansen 4 , Birgitte M Havelund 5 , Lene H Iversen 6,2 , Jonas Funder 6 , Mette M Sørensen 6 , Karen-Lise G Spindler 7,2 1 Aarhus University Hospital, Danish Centre for Particle Therapy, Aarhus, Denmark. 2 Aarhus University, Clinical Medicine, Aarhus, Denmark. 3 Aarhus University Hospital, Radiology, Aarhus, Denmark. 4 Copenhagen university Hospital, Herlev, Oncology, Herlev, Denmark. 5 University Hospital of Southern denmark, Vejle, Oncology, Vejle, Denmark. 6 Aarhus University Hospital, Surgery, Aarhus, Denmark. 7 Aarhus University Hospital, Oncology and Experimental clinical Oncology, Aarhus, Denmark

Purpose/Objective:

Reirradiation of anal cancer recurrences has been done with caution, as the primary treatment requires high dose radiotherapy, resulting in max or near max tolerance doses to organs at risk. Only a few retrospective studies, using reirradiation doses around 40-45 Gy, are published.

The prospective phase II trial, ReRad III/DACG V (Pencil beam proton therapy for recurrences in anal cancer patients previously treated with radiotherapy), evaluates doseescalated proton reirradiation as neo-adjuvant or